| |
KOMISJA NADZORU FINANSOWEGO |
|
| |
|
|
Raport bieżący nr |
17 |
/ |
2020 |
|
|
|
| |
Data sporządzenia: |
2020-06-26 |
|
|
|
|
|
|
|
|
|
| |
Skrócona nazwa emitenta |
|
|
|
|
|
|
|
|
|
| |
MILESTONE MEDICAL |
|
| |
Temat |
|
|
|
|
|
|
|
|
|
|
| |
Milestone Scientic, the Licensor of Milestone Medical Inc. Announces Pricing of 14.0
Million USD Offering of Common Stock and Warrants
|
|
| |
Podstawa prawna |
|
|
|
|
|
|
|
|
| |
Art. 17 ust. 1 MAR - informacje poufne.
|
|
| |
Treść raportu: |
|
|
|
|
|
|
|
|
|
| |
The Board of Directors of Milestone Medical Inc. _WAR: MMD, “the Company", “the Issuer"_,
today announced that Milestone Scientific, Inc. _NYSE:MLSS, "Milestone Scientific"_,
the licensor of the Company’s computer-controlled injection and drug delivery technology
as well as the majority shareholder of the Issuer, intends to to offer for sale a
combination of shares of Milestone Scientific’s common stock and warrants to purchase
shares of its common stock in an underwritten public offering. Milestone Scientific
intends to advance the net proceeds from this offering for manufacturing, marketing,
sales and distribution of its CompluFlo® Epidural System and development of new products
and new product uses, working capital and general corporate purposes. The offering
is subject to market conditions, and there can be no assurance as to whether or when
the offering may be completed, or as to the actual size or terms of the offering.
The Board of Directors of the Issuer also announced the pricing of an underwritten
offering of 6,520,000 shares of its common stock and warrants to purchase up to an
aggregate of 3,260,000 shares of its common stock. Each share of common stock is being
sold together with a warrant to purchase 0.50 of one share of common stock at a combined
price to the public of $2.15. Gross proceeds before underwriting discounts and commissions
and estimated offering expenses, are expected to be approximately $14.0 million.
The warrants will be immediately exercisable at a price of $2.60 per share of common
stock and will expire three years from the date of issuance. The shares of common
stock and the accompanying warrants can only be purchased together in the offering
but will be issued separately and will be immediately separable upon issuance. The
offering is expected to close on or about June 30, 2020, subject to customary closing
conditions.
Maxim Group LLC is acting as sole book-running manager for the offering.
Milestone Scientific also has granted to the underwriter a 45-day option to purchase
up to an additional 978,000 shares of common stock and/or warrants to purchase up
to 489,000 shares of common stock, at the public offering price less discounts and
commissions.
The securities described above are being offered by Milestone Scientific pursuant
to a registration statement _File No. 333-231178_ previously filed and declared effective
by the Securities and Exchange Commission _SEC_. The securities are being offered
by means of a prospectus supplement and accompanying prospectus, forming part of the
registration statement. A preliminary prospectus supplement and accompanying prospectus
relating to this offering have been filed with the SEC.
|
|
|
RB_ASO: Milestone Scientic, the Licensor of Milestone Medical Inc. Announces Pricing of 14.0
Million USD Offering of Common Stock and Warrants 
